Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
In the Literature
ALK-Positive NSCLC Responds to Ceritinib Treatment
In the Literature
May 2014, Vol 5, No 4
Non–small-cell lung cancer (NSC LC) harboring anaplastic lymphoma kinase (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib (Xalkori). Despite initial responses to crizotinib, resistance ultimately occurs. In preclinical studies, ceritinib (Zykadia), a novel, oral adenosine triphosphate–competitive inhibitor of the ALK tyrosine kinase, has shown greater antitumor potency than crizotinib.
Read Article
Dovitinib Active but Not Superior to Sorafenib in Patients with Metastatic Renal Cancer
By
Jayson Slotnik, JD, MPH
In the Literature
April 2014, Vol 5, No 3
Therapies targeting vascular endothelial growth factor (VEGF) and mTOR signaling pathways are standard first-line and second-line treatment options for patients with metastatic renal-cell carcinoma. However, an unmet medical need exists for patients who had previously received VEGF-targeted and mTOR inhibitor therapies.
Read Article
Rituximab Active in Nodular Lymphocyte-Predominant Hodgkin Lymphoma
By
Jayson Slotnik, JD, MPH
In the Literature
April 2014, Vol 5, No 3
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare type of Hodgkin lymphoma that represents approximately 5% of all cases. Unlike classic Hodgkin lymphoma, the malignant cells of NLPHL universally express CD20. Because rituximab (Rituxan) is an anti-CD20 monoclonal antibody, it has been evaluated as a treatment option for this patient population.
Read Article
Personalizing Targeted Treatment Possible for Advanced Breast Cancer
By
Jayson Slotnik, JD, MPH
In the Literature
April 2014, Vol 5, No 3
Metastatic breast cancer is a leading cause of death worldwide, with almost 40,000 women in the United States succumbing to the disease in 2013. Although advances in the treatment of breast cancer have been made, metastatic disease is still largely considered incurable. In a prospective, multicenter, molecular-screening study, researchers investigated whether the identification of individual genomic alterations could lead to personalized targeted therapy in women with advanced breast cancer (André F, et al.
Lancet Oncol
. 2014;15:267-274).
Read Article
Bevacizumab Does Not Improve Survival in Patients with Newly Diagnosed Glioblastoma
By
Jayson Slotnik, JD, MPH
In the Literature
March 2014, Vol 5, No 2
In early clinical studies, bevacizumab (Avastin) showed clinical activity in patients with recurrent glioblastoma. A new randomized, double-blind, placebo-controlled trial investigated whether the use of bevacizumab would improve the OS and PFS of patients with newly diagnosed glioblastoma (Gilbert MR, et al.
N Engl J Med
. 2014;370:699-708).
Read Article
Implications of the Affordable Care Act for Adult Survivors of Childhood Cancer
By
Jayson Slotnik, JD, MPH
In the Literature
March 2014, Vol 5, No 2
Among adult survivors of childhood cancer, the lack of health insurance is a major obstacle to obtaining the recommended follow-up care. The goal of the Patient Protection and Affordable Care Act (ACA) enacted in 2010 was to broaden insurance coverage for all Americans. A new commentary by Mueller and several health policy experts addressed the questions regarding how several provisions in the ACA could help adult survivors of childhood cancers overcome insurance-based barriers to receiving the recommended follow-up care for patients with cancer (Mueller EL, et al.
J Clin Oncol
. 2014;32:615-617).
Read Article
Nintedanib plus Docetaxel an Effective Combination in Patients with Advanced Non–Small-Cell Lung Cancer
By
Jayson Slotnik, JD, MPH
In the Literature
March 2014, Vol 5, No 2
Currently, the US Food and Drug Administration–approved second-line treatments for non–small-cell lung cancer (NSCLC) include monotherapy with docetaxel (Taxotere), erlotinib (Tarceva), or pemetrexed (Alimta). A recent phase 3 clinical trial explored the safety and efficacy of nintedanib (Vargatef)—a potent oral angiokinase inhibitor—in combination with docetaxel, as a second-line treatment in patients with NSCLC (Reck M, et al.
Lancet Oncol
. 2014;15:143-155).
Read Article
Bortezomib plus Thalidomide Maintenance Therapy Improves Overall Survival in Transplant-Ineligible Patients with Newly Diagnosed Myeloma
By
Jayson Slotnik, JD, MPH
In the Literature
March 2014, Vol 5, No 2
Patients with multiple myeloma (MM) who are not fit to undergo stem-cell transplantation (SCT), typically receive melphalan (Alkeran) plus prednisone in combination with either thalidomide (Thalomid) or bortezomib (Velcade). Recent studies are exploring the clinical benefit of the 4-drug induction regimen of melphalan, prednisone, bortezomib, and thalidomide, followed by maintenance with bortezomib plus thalidomide (VMPT-VT). In a recent phase 3 clinical trial, a total of 511 patients with newly diagnosed MM who were not candidates for SCT were randomized to receive VMPT-VT (N = 254) or bortezomib, melphalan, and prednisone (VMP; N = 257). The patients’ median age was 71 years, and 27% of the patients were aged >75 years (Palumbo A, et al.
J Clin Oncol
. 2014;32:634-640).
Read Article
Statin Therapy Lowers Mortality in Patients with Prostate Cancer
By
Jayson Slotnik, JD, MPH
In the Literature
February 2014, Vol 5, No 1
In a new study, researchers examined the correlation between the use of statins after a prostate cancer diagnosis and the risk of cancer-related and all-cause mortality (Yu O, et al.
J Clin Oncol
. 2014;32:5-11).
Read Article
New Gene Mutation Identified in Myeloproliferative Neoplasms
By
Jayson Slotnik, JD, MPH
In the Literature
February 2014, Vol 5, No 1
New research shows promise in deciphering the underlying mechanism of myeloproliferative neoplasms (MPNs), according to findings from a recently reported study (Klampfl T, et al.
N Engl J Med
. 2013;369:2379-2390).
Read Article
Page 6 of 13
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma